Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol/Medarex Ipilimumab Toxicity Signals Efficacy, Investigator Says

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The immune response side effects of ipilimumab serve as an efficacy signal for the melanoma therapy, according to one of the lead investigators studying the Bristol-Myers Squibb/Medarex immunotherapeutic

You may also be interested in...

ASCO Abstracts Hold Some Surprises Including Data On AZ’s Vandetanib, Bristol’s Ipilimumab

Despite the lack of innovative drugs highlighted in ASCO's media briefing on its upcoming annual meeting, there is a range of oncology development updates that will be presented - including some surprises

A Round-Up Of Oncology Vaccine Data At ASCO


R&D In Brief

Motavizumab reduced hospitalization in Phase III trial: MedImmune's motavizumab reduced hospitalizations due to respiratory syncytial virus by 83 percent compared to placebo in a Phase III trial, the firm says May 4. The monoclonal antibody is being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. The trial showed a 71 percent reduction in the incidence of RSV-specific lower respiratory infections requiring outpatient management, which was the study's secondary endpoint. The randomized, double-blind study involved 1,410 full-term healthy infants less than six months old in certain Southwest Native American populations and was designed to compare monthly intramuscular injections of motavizumab against placebo. The study confirmed what previous epidemiological studies have shown: that these populations have high rates of hospitalization due to RSV. Motavizumab would be a follow-on to AstraZeneca's Synagis (palivizumab)


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts